Clinical trial
Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With…
NCT00290771 · Novartis, Industry · Terminated
Key facts
| NCT number | NCT00290771 |
|---|---|
| Title | Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM) |
| Official title | A Phase II, Open-label, Multicenter Study Evaluating the Efficacy of Imatinib Plus Hydroxyurea (HU) in Patients With Progressive Glioblastoma Multiforme (GBM) Receiving or Not Receiving Enzyme-inducing Anticonvulsant Drugs (EIACDs) |
| Lead sponsor | Novartis, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Glioblastoma Multiforme (GBM) |
| Intervention type | Drug |
| Interventions | Imatinib tablets, Hydroxyurea capsules |
| Enrollment | 231 |
| Start date | Feb 1, 2006 |
| Primary completion | Aug 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | Feb 13, 2006 |
| Last update posted | May 16, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: